>>3 Dividend Stocks for a Richer Retirement<< (sponsored)
Holdings Channel Holdings Channel 13F research and institutional holdings

BSX Insider Buying

The table below summarizes the most recent Boston Scientific insider buying information — the latest buy being $100,407.78 by Susan E. Morano on 8/25/2026, with links to see the CAGR achieved by each insider on their purchases. As the saying goes on Wall Street, there are many possible reasons to sell a stock, but only one reason to buy. Watch the importance of insider buying video for more information about why Boston Scientific insider buys like these are important for investors to follow.
Boston Scientific insider buying image
DateInsiderPriceAmount
8-25-2026
Insider Buy		 Susan E. Morano
Director		 $49.22
CAGR » 		$100,407.78
2,040 shares
8-5-2026
Insider Buy		 David C. Habiger
Director		 $47.59
CAGR » 		$99,936.90
2,100 shares
8-4-2026
Insider Buy		 David C. Habiger
Director		 $48.13
CAGR » 		$56,886.56
1,182 shares
8-3-2026
Insider Buy		 Michael F. Mahoney
Chairman, President & CEO		 $48.33
CAGR » 		$9,001,407.55
186,240 shares
7-31-2026
Insider Buy		 Edward J. Ludwig
Director		 $45.48
CAGR » 		$227,399.50
5,000 shares
5-20-2026
Insider Buy		 David C. Habiger
Director		 $56.43
CAGR » 		$251,098.10
4,450 shares
5-20-2026
Insider Buy		 Edward J. Ludwig
Director		 $56.68
CAGR » 		$202,914.40
3,580 shares
5-20-2026
Insider Buy		 Cheryl Pegus
Director		 $56.49
CAGR » 		$99,987.30
1,770 shares
2-11-2025
Insider Buy		 Joseph Michael Fitzgerald
EVP & Group Pres, Cardiology		 $90.29
CAGR » 		$4,514.60
50 shares
11-15-2021
Insider Buy		 David S. Wichmann
Director		 $41.98
CAGR » 		$1,049,450.00
25,000 shares
9-1-2017
Insider Buy		 John E. Sununu
Director		 $26.83
CAGR » 		$1,931.58
72 shares
2-12-2016
Insider Buy		 Charles J. Dockendorff
Director		 $16.49
CAGR » 		$494,688.00
30,000 shares
8-21-2015
Insider Buy		 John E. Abele
 $16.77
CAGR » 		$3,354,330.00
200,000 shares
8-19-2015
Insider Buy		 John E. Abele
 $17.48
CAGR » 		$3,496,410.00
200,000 shares
8-17-2015
Insider Buy		 John E. Abele
 $17.50
CAGR » 		$1,749,530.00
100,000 shares
11-28-2014
Insider Buy		 Michael F. Mahoney
President & CEO		 $12.89
CAGR » 		$150,831.72
11,700 shares
11-10-2014
Insider Buy		 Edward J. Ludwig
Director		 $13.38
CAGR » 		$133,836.00
10,000 shares
5-6-2013
Insider Buy		 Ernest Mario
Director		 $7.76
CAGR » 		$232,800.00
30,000 shares
11-13-2012
Insider Buy		 NJ Nicholas Jr.
Director		 $5.28
CAGR » 		$105,595.50
20,000 shares
11-9-2012
Insider Buy		 NJ Nicholas Jr.
Director		 $5.17
CAGR » 		$129,304.50
25,000 shares
8-6-2012
Insider Buy		 Ernest Mario
Director		 $5.29
CAGR » 		$169,280.00
32,000 shares
7-31-2012
Insider Buy		 William Kucheman
Chief Executive Officer		 $5.21
CAGR » 		$52,089.00
10,000 shares
7-31-2012
Insider Buy		 Michael F. Mahoney
President		 $5.19
CAGR » 		$114,133.80
22,000 shares
2-23-2012
Insider Buy		 Ernest Mario
Director		 $5.91
CAGR » 		$59,100.00
10,000 shares
2-22-2012
Insider Buy		 Ernest Mario
Director		 $5.93
CAGR » 		$59,300.00
10,000 shares
2-21-2012
Insider Buy		 Ernest Mario
Director		 $6.12
CAGR » 		$122,400.00
20,000 shares
11-29-2011
Insider Buy		 NJ Nicholas Jr.
Director		 $5.56
CAGR » 		$55,600.00
10,000 shares
11-28-2011
Insider Buy		 Katharine T. Bartlett
Director		 $5.42
CAGR » 		$43,360.00
8,000 shares
11-28-2011
Insider Buy		 Ernest Mario
Director		 $5.40
CAGR » 		$540,000.00
100,000 shares
11-21-2011
Insider Buy		 Ernest Mario
Director		 $5.30
CAGR » 		$132,500.00
25,000 shares
10-26-2011
Insider Buy		 Ernest Mario
Director		 $5.45
CAGR » 		$136,250.00
25,000 shares
10-25-2011
Insider Buy		 Ernest Mario
Director		 $5.50
CAGR » 		$137,500.00
25,000 shares
8-3-2011
Insider Buy		 Ernest Mario
Director		 $6.70
CAGR » 		$669.80
100 shares
8-2-2011
Insider Buy		 Ernest Mario
Director		 $6.82
CAGR » 		$682,230.00
100,000 shares
5-23-2011
Insider Buy		 NJ Nicholas Jr.
Director		 $6.57
CAGR » 		$65,700.00
10,000 shares
5-17-2011
Insider Buy		 Ernest Mario
Director		 $6.72
CAGR » 		$1,827.84
272 shares
5-13-2011
Insider Buy		 NJ Nicholas Jr.
Director		 $6.78
CAGR » 		$135,500.00
20,000 shares

Also See: Institutional Holders of BSX
Also See: SEC filings


Boston Scientific Insider Purchase CAGR Analysis

BSX Performance Since Insider Purchase
Below we present the annualized performance delivered by Boston Scientific stock since 8-25-2026 (the date of the most recent insider purchase). The performance of the investment from the time Boston Scientific insider buying occurred is the ultimate test of whether insiders were right about BSX being a good buy.

Growth of $10,000.00
Without Dividends Reinvested
Start date: 08/26/2026
End date: 10/06/2026
Start price/share: $48.17
End price/share: $42.19
Dividends collected/share: $0.00
Total return: -12.41%
Annualized Gain: -110.52%
Starting investment: $10,000.00
Ending investment: $8,759.00
Years: 0.11

Which BSX Insiders Report Buying

This Holdings Channel page has presented insider buying activity, covering Directors, officers (such as CEO, CFO, COO, etc.), and >10% owners (who are required to file form 4's with the SEC). Important institutional owners may not fall under these categories, but instead file their holdings quarterly on the latest form 13F filings. While recent Boston Scientific insider buying activity is included, there may also be stock sales over this same period (Also See: SEC filings for sales and other details).

Also See: Funds Holding BSX

BSX Insider Buying: Recent Boston Scientific Purchases by Company Insiders | www.HoldingsChannel.com | Copyright © 2013 - 2026, All Rights Reserved

Nothing in Holdings Channel is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. Holdings Channel is not affiliated with, endorsed by, or sponsored by any investment manager listed on this site. Company, fund, ETF, and investment manager names are used for identification and informational purposes only. Holdings data is based on publicly available regulatory filings and other market data sources. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent. Contact Holdings Channel; Meet Our Editorial Staff.